Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02471690 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers
A Phase 1 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT02471690 is a Phase 1 study that has completed, run by The Medicines Company. The registered enrollment target is 56 participants.
The verdict
NCT02471690, a Phase 1 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The protocol describes a double-blind study to evaluate the Pharmacokinetics and safety of a new formulation of oritavancin by adjusting infusion time, concentration and reconstitution/administration solutions, of a single 1200 mg intravenous (IV) infusion of oritavancin
Interventions
- DRUG Dextrose
- DRUG Oritavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02471690
The ClinicalTrials.gov registry entry for NCT02471690 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dextrose is the first listed.
NCT02471690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02471690 about?
NCT02471690 is a clinical study titled "Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers". The protocol describes a double-blind study to evaluate the Pharmacokinetics and safety of a new formulation of oritavancin by adjusting infusion time, concentration and reconstitution/administration solutions, of a single 1200 mg intravenous (IV) infusion of oritavancin
What is the current status of trial NCT02471690?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2015-07. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02471690?
The interventions under investigation include: Dextrose (DRUG), Oritavancin (DRUG).
Who is sponsoring clinical trial NCT02471690?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.